News & Publications

Pharmaceutical & Biotechnology Report Available Now

Pharmaceutical & Biotechnology Sector Report

Pharmaceutical & Biotechnology Sector Report

In our newly published report on the Pharmaceutical & Biotechnology Sector, we look at the Key Findings, performances and trends in the sector, takeaways on Risks & Opportunities, and more. V.E’s Pharmaceuticals and Biotechnology sector is composed of 188 companies. These companies are engaged in the research, development, manufacturing, and distribution of drugs for human or veterinary use. The medicines produced are aimed to cure or manage diseases, or to prevent from infection.

The industry’s value chain starts with the manufacturing of medicines that involves research and development in addition to regulatory approval. The second phase includes the distribution and the handling of medicines from the manufacturer to the end user (through retail, pharmacy, hospital, or dispensing doctors). The final step in the value chain is the commercialisation and the provision of the right medicine dosage, form, and advice to the right patient.

The Pharmaceuticals & Biotechnology sector is composed of two broad sub-sectors: biotechnology companies and traditional pharmaceuticals and the primary difference between the two is the method by which the drugs are produced:

 

  • Pharmaceutical companies manufacture drugs through a series of chemical synthesis. Based on their size and strategy, pharmaceutical companies may conduct extensive in-house research or seek to license drugs from other pharmaceutical or biotechnology companies. Some pharmaceutical companies are considered as specialty pharma since they focus only on specific activities such as R&D only or marketing and sales only. Pharmaceutical companies generally hold the exclusive rights to manufacture and distribute their drugs for five years.
  • Biotechnology companies produce drugs with a biological basis that are manufactured in living organisms such as bacteria or enzymes. These companies are working to duplicate or change the function of a living cell and could use genetics research to develop products for human diseases and conditions. Biotechnology companies hold their patents for 12 years.

 

Read the FULL sector report in the link below.

To learn more about how we can help you on your sustainability journey, please contact sustainabilityrating@vigeo-eiris.com or visit our Sustainability Rating Services page.

Register NOW for our upcoming webinar on ESG Trends in the Pharmaceutical & Biotechnology Industry.

Share this!

Related posts